Arcturus' topical dexchlorpheniramine enters Phase Ib/II trials as anti-itch treatment.
This article was originally published in The Tan Sheet
Executive Summary
ARCTURUS BEGINS TOPICAL DEXCHLORPHENIRAMINE PHASE Ib/II STUDY as an anti-itch treatment for contact and atopic dermatitis, the dermatological R&D company announced Jan. 31. Arcturus Pharmaceutical said it expects the trial, which is a dose-escalating study in patients with atopic dermatitis, to be completed by the second half of 1995. The company hopes to begin Phase III efficacy trials by the end of the year.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: